The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
Completed
Bayer
Phase 2
2006-09-01
The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients
with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial
remission after 6 cycles of CHOP therapy.
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
Completed
Mahidol University
Phase 2
2006-09-01
The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients
with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial
remission after 6 cycles of CHOP therapy.
Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
Completed
Federico II University
Phase 4
1995-01-01
Epidemiological data indicate that patients with active acromegaly have reduced life
expectancy because of cardiovascular (60%) and respiratory diseases (25%) mainly (1-10). A
post-treatment GH value
Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer
Unknown status
Royal Marsden NHS Foundation Trust
N/A
2007-11-01
RATIONALE: Diagnostic procedures, such as multifunctional magnetic resonance imaging, may
help doctors learn the extent of disease and plan the best treatment.
PURPOSE: This clinical trial is studying how well multifunctional magnetic resonance imaging
works in predicting breast lesions in women undergoing mastectomy for breast cancer.
Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion
Completed
Phoenix Children's Hospital
Phase 1
2010-04-01
DMPS is a metal chelator which is approved for use in Europe. While not an FDA-approved drug
in the US, it is easily obtained and administered by alternative health practitioners to
their patients. A formulation called 'TD DMPS' (transdermal DMPS) is in use, despite the fact
there is no published literature to support that the agent is absorbed transdermally. The
investigators hypothesis is that DMPS is not absorbed through the skin. The investigators
plan to apply TD DMPS to healthy volunteers and then test serum for presence of DMPS. In
addition the investigators will measure urinary mercury concentrations pre and post DMPS
application.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
